ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

LCAR Lescarden Inc (CE)

0.000001
0.00 (0.00%)
Apr 18 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0.00
Bid Price
Ask Price
News -
Company Name Stock Ticker Symbol Market Type
Lescarden Inc (CE) LCAR OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 0.000001 20:00:00
Open Price Low Price High Price Close Price Prev Close
0.000001 0.000001
Trades Volume Avg Volume
0 0.00 -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.000001 USD

Lescarden Inc (CE) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 63.62 63.62M - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Lescarden (CE) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No LCAR Message Board. Create One! See More Posts on LCAR Message Board See More Message Board Posts

Historical LCAR Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.001320.0140.0000010.001771443,521-0.00132-99.92%
5 Years0.0050.0140.0000010.002767963,442-0.005-99.98%

Lescarden (CE) Description

Since its inception in 1960, Lescarden has devoted its resources to fund research and development of proprietary biologic materials with a focus on wound healing, clinical skin care, osteoarthritis and cancer applications. In the ensuing years, significant studies substantiated the ability of Catrix, Lescarden's proprietary cartilage powder, to function as a biological response modifier by stimulating the body's immune system. This response has significant, demonstrated benefits for chronic wound management, and has been investigated as a potential treatment for certain types of cancer. Further studies indicated that Catrix has potent anti-inflammatory properties that could also be effective against diseases such as arthritis, scleroderma and psoriasis. With a solid clinical platform, the Company in recent years has focused its strategy toward pursuing marketing and licensing opportunities for fully developed products that have received patents and are ready for commercialization.

Your Recent History

Delayed Upgrade Clock